chr7-92077826-A-G
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_005751.5(AKAP9):āc.6896A>Gā(p.Glu2299Gly) variant causes a missense change. The variant allele was found at a frequency of 0.000183 in 1,613,670 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005751.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AKAP9 | NM_005751.5 | c.6896A>G | p.Glu2299Gly | missense_variant | 30/50 | ENST00000356239.8 | NP_005742.4 | |
AKAP9 | NM_147185.3 | c.6872A>G | p.Glu2291Gly | missense_variant | 30/50 | NP_671714.1 | ||
AKAP9 | NM_001379277.1 | c.1541A>G | p.Glu514Gly | missense_variant | 9/29 | NP_001366206.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152152Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000120 AC: 30AN: 250718Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135548
GnomAD4 exome AF: 0.000193 AC: 282AN: 1461518Hom.: 0 Cov.: 31 AF XY: 0.000191 AC XY: 139AN XY: 727076
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152152Hom.: 0 Cov.: 31 AF XY: 0.0000807 AC XY: 6AN XY: 74346
ClinVar
Submissions by phenotype
Long QT syndrome 11 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 05, 2020 | The p.Glu2299Gly variant (rs147841245) has not been reported in the medical literature nor has it been previously identified in our laboratory; however, it is listed in the ClinVar database as a variant of uncertain significance (Variation ID: 360836). It is listed in the Genome Aggregation Database (gnomAD) browser with a frequency in non-Finnish Europeans of 0.021% (identified in 27 out of 126,200 chromosomes). The glutamic acid at codon 2299 is highly conserved considering 11 species up to Cow (Alamut software v2.9), although computational analyses return mixed results regarding the effect of this variant on AKAP9 protein structure/function (SIFT: damaging, PolyPhen2: benign, and Mutation Taster: disease causing). Therefore, based on the available information, the clinical significance of the p.Glu2299Gly variant cannot be determined with certainty. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 03, 2021 | - - |
Congenital long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Long QT syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 10, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 360836). This variant has not been reported in the literature in individuals affected with AKAP9-related conditions. This variant is present in population databases (rs147841245, gnomAD 0.02%). This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 2299 of the AKAP9 protein (p.Glu2299Gly). - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 18, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at